Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics
Foghorn plans to layoff 40% of its staff.
Foghorn Therapeutics Inc. (FHTX)
Market is closed
Sector: Investment Advice
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 137,435 | $490,643 | +6% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 5,500 | $88,000.00 | 258,397 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | $800,000.00 | 1,851,801 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | $800,000.00 | 1,491,441 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | $800,000.00 | 9,330,878 | 2020-10-27 | Filing | |
| $16.00 | 150,000 | $2,400,000.00 | 1,231,081 | 2020-10-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.17 | 857 | $8,715.69 | 0 | 2024-09-23 | Filing | |
| $10.04 | 35,756 | $358,990.24 | 0 | 2024-09-20 | Filing | |
| $10.05 | 11,574 | $116,318.70 | 0 | 2024-09-18 | Filing | |
| $10.04 | 10,272 | $103,130.88 | 0 | 2024-09-17 | Filing | |
| $10.00 | 400 | $4,000.00 | 0 | 2024-09-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,546,349 | $19,800,465 | 0% | |
| 2. | 861,655 | $3,076,895 | 0% | |
| 3. | 313,765 | $1,124,234 | 0% | |
| 4. | 151,354 | $540,334 | 0% | |
| 5. | 126,500 | $451,605 | 0% |
News See All
5 Best Biotech and AI Stocks To Buy According To Billionaire Jim Simons
In this article, we discuss 5 stock picks of Jim Simons’ Euclidean Capital.
10 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we reviewed Jim Simons' investment strategy, historical performance, and family office portfolio.
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital. Jim Simons is the President of Euclidean Capital, a family office.
Hedge Fund Resource Center